Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

• ClinicalTrials.gov Identifier: NCT04239170
• Recruitment Status: Unknown
• First Posted: January 23, 2020
• Last Update Posted: January 23, 2020
• Sponsor: Peking University
• Information provided by (Responsible Party): Jun Zhu, Peking University

Study Description

Brief Summary:

This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano criteria.

Condition or disease	Intervention/treatment	Phase
Hodgkin Lymphoma	Drug: Camrelizumab(SHR-1210)	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 84 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-lable, Single Arm, Phase 2 Study of Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Will Receive ASCT
• Estimated Study Start Date: January 2020
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: December 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Camrelizumab(SHR-1210) Combined With GEMOX	Drug: Camrelizumab(SHR-1210); Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin; Other Name: GEMOX(Gemcitabine, Oxaliplatin)

Outcome Measures

Primary Outcome Measures :

1. Complete Response [ Time Frame: From first patient first visit to 3 month after last patient first visit ]
   Based on Lugano 2014 criteria

Secondary Outcome Measures :

1. Objective Response Rate [ Time Frame: From first patient first visit to 3 month after last patient first visit ]
   Rate of subjects achieved complete response plus partial response in all evaluable subjects

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically confirmed classic Hodgkin's lymphoma ;
2. Relapsed or refractory cHL and meet any of the following criterions:a)did not achieve remission or progression and will receive autologous hematopoietic stem cell transplantation.b)receive no more than 3 lines of systemic chemotherapy.
3. Subjects enrolled have measurable lesion(s) according to Lugano 2014 criteria
4. ECOG performance status of 0 or 1;
5. Life expectancy ≥ 12 weeks.;

6. Adequate laboratory parameters during the screening period as evidenced by the following:

   1. Hemoglobin ≥ 90 g/L;
   2. Absolute neutrophil count ≥ 1.5 × 109/L ;
   3. Platelets ≥ 100 × 109/L;
   4. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN),
   5. ALT and AST ≤ 2.5×ULN
   6. Serum Creatinine ≤1.25×ULN or Creatinine clearance≥60 mL/min;
   7. Coagulation function index：INR ≤1.5×ULN，APTT≤1.5×ULN
7. Women of childbearing potential（WOCBP）with pregnancy test negative within 7 days before entering the group and consent to employ a highly effective method of birth control/contraception to prevent pregnancy for at least 1 year after receiving the last dose of study treatment; Male subjects with WOCBP partner should receive Surgical sterilization or consent to employ a highly effective method of birth control/contraception to prevent pregnancy for at least 1 year after receiving the last dose of study treatment.
8. Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

1. Known nodular lymphoma predominant Hodgkin lymphoma

2. History and complication as follows,

   1. Active, known or suspected autoimmune disease. Subjects who were in a stable state without systemic immunosuppressive therapy were admitted
   2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids > 10 mg/day topical prednisone or equivalent are prohibited within 2 weeks before entering the group
   3. Received anti-tumor vaccines or other anti-tumor therapy with immune stimulation within 3 months before the first dose of trial drugs.
   4. Prior exposure to any PD-1/PD-L1/PD -L 2 or CTLA -4 antibody . Or prior exposure to GEMOX but PD.
   5. Participating in other clinical studies or less than 4 weeks before the end of a clinical trial.
   6. Known and highly Suspicion of interstitial pneumonia.
   7. Other active malignancies that required treating. (subjects with skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma or cervical carcinoma who had no disease recurrence within 5 years after the start of treatment were excluded).
   8. Received chemotherapy, radiotherapy,immunotherapy, including topical therapy within 4 weeks. Previous anti-tumor therapy related adverse reactions (except hair loss) did not recover to CTCAE ≤1.
   9. Prior allo-HSCT.
   10. Impact of major surgery or severe trauma had been eliminated for less than 28 days
   11. Active pulmonary tuberculosis.
   12. Severe acute or chronic infection requiring systemic therapy.
   13. Suffering from high blood pressure, and cannot be well controlled by antihypertensive drugs (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg)
   14. Suffering from heart failure (New York Heart Association standard III or IV). Uncontrolled coronary artery disease and arrhythmia although given appropriate medical treatment. History of myocardial infarction within 6 months.
   15. Three months before randomization, there were significant bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcer, stool occult blood test is ++ at baseline and above, or vasculitis

3. Laboratory test

   1. Known HIV positive or known AIDS.
   2. Untreated active hepatitis: Hepatitis B(HBsAg positive and HBV DNA≥500IU/mL), and hepatitis C(HCV RNA positive, abnormal liver function) ,Hepatitis B and hepatitis C infection in common.
4. Other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subjects safety or test data and sample collection.
5. Pregnant or lactating women.

Contacts and Locations

Contacts

Contact: Yuqin Song, MD; (+8610)88196118; SongYQ_VIP@163.com

Locations

China, Beijing

Beijing Cancer Hospital; Recruiting

Beijing, Beijing, China

Contact: Jun Zhu, MD (+8610)88196596 Zj@bjcancer.org

Sponsors and Collaborators

Peking University

More Information

• Responsible Party: Jun Zhu, Party secretary of Cancer Hospital of Peking University, Director of Internal Medicine, Peking University
• ClinicalTrials.gov Identifier: NCT04239170
• Other Study ID Numbers: SHR-1210-GEMOX-IIT-HL
• First Posted: January 23, 2020
• Last Update Posted: January 23, 2020
• Last Verified: January 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lymphoma; Hodgkin Disease; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Gemcitabine; Oxaliplatin; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents